An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 10, 2015, Pages H1287-H1297

  Ihara, Madoka ^a   Asanuma, Hiroshi ^b   Yamazaki, Satoru ^a   Kato, Hisakazu ^c   Asano, Yoshihiro ^c   Shinozaki, Yoshihiro ^d   Mori, Hidezo ^d   Minamino, Tetsuo ^c   Asakura, Masanori ^a   Sugimachi, Masaru ^a   Mochizuki, Naoki ^a   Kitakaze, Masafumi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKAI UNIVERSITY   (Japan)

Author keywords

Adenosine; Cardioprotection; Dipeptidyl peptidase 4 inhibitor; Ischemia reperfusion injury; Myocardial infarction

Indexed keywords

ADENOSINE; ALOGLIPTIN; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME C; GLUCAGON LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; THEOPHYLLINE DERIVATIVE; ADENOSINE DEAMINASE; ADENOSINE RECEPTOR BLOCKING AGENT; CARDIOTONIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MITOGEN ACTIVATED PROTEIN KINASE; PIPERIDINE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE B; THEOPHYLLINE; URACIL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; APOPTOSIS; ARTICLE; COLLATERAL CIRCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; CYTOSOLIC FRACTION; EXPERIMENTAL DOG; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEMODYNAMIC PARAMETERS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TUNEL ASSAY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DOG; HEMODYNAMICS; METABOLISM; MYOCARDIAL REPERFUSION INJURY;

ADENOSINE; ADENOSINE DEAMINASE; ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOGS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE 3; HEMODYNAMICS; MYOCARDIAL REPERFUSION INJURY; PIPERIDINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; PURINERGIC P1 RECEPTOR ANTAGONISTS; THEOPHYLLINE; URACIL;

EID: 84930835679     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00835.2014     Document Type: Article

References (57)

1. Abd-Elfattah AS, Ding M, Dyke CM, Wechsler AS. Protection of the stunned myocardium. Selective nucleoside transport blocker administered after 20 minutes of ischemia augments recovery of ventricular function. Circulation 88: II336–II343, 1993.
2. Asanuma H, Sanada S, Ogai A, Minamino T, Takashima S, Asakura M, Ogita H, Shinozaki Y, Mori H, Node K, Tomoike H, Hori M, Kitakaze M. Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts. J Cardiovasc Pharmacol 43: 574–579, 2004.
3. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, Drucker DJ, Husain M. Glucagon-like peptide (GLP)-1(9 –36)amidemediated cytoprotection is blocked by exendin(9 –39) yet does not require the known GLP-1 receptor. Endocrinology 151: 1520–1531, 2010.
4. Bell JD, Buxton IL, Brunton LL. Enhancement of adenylate cyclase activity in S49 lymphoma cells by phorbol esters. Putative effect of C kinase on alpha s-GTP-catalytic subunit interaction. J Biol Chem 260: 2625–2628, 1985.
5. Bruns RF, Daly JW, Snyder SH. Adenosine receptors in brain membranes: binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8- [3H]phenylxanthine. Proc Natl Acad Sci USA 77: 5547–5551, 1980.
6. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17: 819–837, 2013.
7. Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol 167: 451–457, 2013.
8. Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 103: 203–215, 2008.
9. Cooper DM, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature 374: 421–424, 1995.
10. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, Greenberg ME. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 6: 41–51, 2000.
11. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696–1705, 2006.
12. Fan H, Tansi FL, Weihofen WA, Bottcher C, Hu J, Martinez J, Saenger W, Reutter W. Molecular mechanism and structural basis of interactions of dipeptidyl peptidase IV with adenosine deaminase and human immunodeficiency virus type-1 transcription transactivator. Eur J Cell Biol 91: 265–273, 2012.
13. Guerra GP, Mello CF, Bochi GV, Pazini AM, Rosa MM, Ferreira J, Rubin MA. Spermidine-induced improvement of memory involves a cross-talk between protein kinases C and A. J Neurochem 122: 363–373, 2012.
14. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61: 448–460, 2004.
15. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 167: 87–93, 2013.
16. Holly TA, Drincic A, Byun Y, Nakamura S, Harris K, Klocke FJ, Cryns VL. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 31: 1709–1715, 1999.
17. Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell 103: 839–842, 2000.
18. Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 25: 13–20, 2011.
19. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261: 466–469, 1993.
20. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035–2038, 1979.
21. Keranen LM, Dutil EM, Newton AC. Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr Biol 5: 1394–1403, 1995.
22. Kitakaze M, Funaya H, Minamino T, Node K, Sato H, Ueda Y, Okuyama Y, Kuzuya T, Hori M, Yoshida K. Role of protein kinase C-alpha in activation of ecto-5=-nucleotidase in the preconditioned canine myocardium. Biochem Biophys Res Commun 239: 171–175, 1997.
23. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, et al. Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5=-nucleotidase activity. J Clin Invest 93: 2197–2205, 1994.
24. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, et al. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5=-nucleotidase activity and attenuation of adenosine release. Circulation 89: 1237–1246, 1994.
25. Kitakaze M, Hori M, Takashima S, Sato H, Inoue M, Kamada T. Ischemic preconditioning increases adenosine release and 5=-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implications for myocardial salvage. Circulation 87: 208–215, 1993.
26. Ku HC, Chen WP, Su MJ. DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol 384: 197–207, 2011.
27. Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 589: 306–314, 2008.
28. Lee CH, Yan B, Yoo KY, Choi JH, Kwon SH, Her S, Sohn Y, Hwang IK, Cho JH, Kim YM, Won MH. Ischemia-induced changes in glucagon- like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 89: 1103–1113, 2011.
29. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84: 350–356, 1991.
30. Lonborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Køber L, Treiman M, Holst JJ, Engstrom T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33: 1491–1499, 2012.
31. Mao LM, Tang Q, Wang JQ. Protein kinase C-regulated cAMP response element-binding protein phosphorylation in cultured rat striatal neurons. Brain Res Bull 72: 302–308, 2007.
32. Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetol 40, Suppl 2: S358–S361, 2003.
33. Mori H, Haruyama S, Shinozaki Y, Okino H, Iida A, Takanashi R, Sakuma I, Husseini WK, Payne BD, Hoffman JI. New nonradioactive microspheres and more sensitive X-ray fluorescence to measure regional blood flow. Am J Physiol Heart Circ Physiol 263: H1946–H1957, 1992.
34. Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 177: 1135–1143, 1993.
35. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962–965, 2004.
36. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975–983, 2009.
37. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609–619, 1993.
38. Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H, Gatell JM, Gallart T, Mallol J, Lluis C, Franco R. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci USA 102: 9583–9588, 2005.
39. Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res 94: 316–323, 2012.
40. Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol 301: H1723–H1741, 2011.
41. Santafe MM, Garcia N, Lanuza MA, Tomas M, Tomas J. Interaction between protein kinase C and protein kinase A can modulate transmitter release at the rat neuromuscular synapse. J Neurosci Res 87: 683–690, 2009.
42. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317–1326, 2013.
43. Tan Y, Demeter MR, Ruan H, Comb MJ. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem 275: 25865–25869, 2000.
44. Van Linden A, Eltzschig HK. Role of pulmonary adenosine during hypoxia: extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. Expert Opin Biol Ther 7: 1437–1447, 2007.
45. Wang TD, Chen WJ, Mau TJ, Lin JW, Lin WW, Lee YT. Attenuation of increased myocardial ischaemia-reperfusion injury conferred by hypercholesterolaemia through pharmacological inhibition of the caspase-1 cascade. Br J Pharmacol 138: 291–300, 2003.
46. Weihofen WA, Liu J, Reutter W, Saenger W, Fan H. Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J Biol Chem 279: 43330–43335, 2004.
47. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369: 1327–1335, 2013.
48. Yamazaki S, Iwamoto R, Saeki K, Asakura M, Takashima S, Yamazaki A, Kimura R, Mizushima H, Moribe H, Higashiyama S, Endoh M, Kaneda Y, Takagi S, Itami S, Takeda N, Yamada G, Mekada E. Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J Cell Biol 163: 469–475, 2003.
49. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285–291, 1995.
50. Yao L, Fan P, Jiang Z, Gordon A, Mochly-Rosen D, Diamond I. Dopamine and ethanol cause translocation of epsilonPKC associated with epsilonRACK: cross-talk between cAMP-dependent protein kinase A and protein kinase C signaling pathways. Mol Pharmacol 73: 1105–1112, 2008.
51. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 298: H1454–H1465, 2010.
52. Yin M, Sillje HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 10: 85, 2011.
53. Yoshida A, Asanuma H, Sasaki H, Sanada S, Yamazaki S, Asano Y, Shinozaki Y, Mori H, Shimouchi A, Sano M, Asakura M, Minamino T, Takashima S, Sugimachi M, Mochizuki N, Kitakaze M. H(2) mediates cardioprotection via involvements of K(ATP) channels and permeability transition pores of mitochondria in dogs. Cardiovasc Drugs Ther 26: 217–226, 2012.
54. Yoshimura M, Cooper DM. Type-specific stimulation of adenylylcyclase by protein kinase C. J Biol Chem 268: 4604–4607, 1993.
55. Zanassi P, Paolillo M, Feliciello A, Avvedimento EV, Gallo V, Schinelli S. cAMP-dependent protein kinase induces cAMP-response element-binding protein phosphorylation via an intracellular calcium release/ ERK-dependent pathway in striatal neurons. J Biol Chem 276: 11487–11495, 2001.
56. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619–628, 1996.
57. Zhao ZQ, Morris CD, Budde JM, Wang NP, Muraki S, Sun HY, Guyton RA. Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc Res 59: 132–142, 2003.